TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01469065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0499132
Description: Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
Study: NCT00376935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palifermin placebo
Description: Keratinocyte growth factor placebo administered via injection
Study: NCT01469065

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
Study: NCT01282593

Intervention type: OTHER
Group type: OTHER
Intervention: Impact of CD9 expression level on motility assays
Description: 1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL.

Intervention type: OTHER
Group type: OTHER
Intervention: Post-transcriptional regulation of CD9
Description: 2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples.
Study: NCT01583010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANV(R)
Description: Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group
Study: NCT02016963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Raxibacumab
Description: Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
Study: NCT03191916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (for transcranial direct current stimulation)
Description: For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
Study: NCT00915798

Intervention type: BEHAVIORAL
Intervention: Cigarette smoking
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.

Intervention type: BEHAVIORAL
Intervention: Cigarette smoking
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.

Intervention type: BEHAVIORAL
Intervention: Abstinence
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.

Intervention type: BEHAVIORAL
Intervention: Abstinence
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.

Intervention type: BEHAVIORAL
Intervention: Abstinence
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
Study: NCT03438968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Cardiac Rehabilitation exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Cardiac Rehabilitation exercise training
Study: NCT01873352

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: renal sympathetic denervation
Description: Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
Study: NCT01588288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Galectin 3 dosage
Description: Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
Study: NCT02554071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist - Smoking Cessation Support
Description: Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
Study: NCT04324424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg
Study: NCT03499639

Intervention type: DRUG
Group type: OTHER
Intervention: Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
Description: * Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~* Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks.
Study: NCT00743925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varespladib Methyl (A-002)
Description: 2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varespladib Methyl (A-002)
Description: 2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
Study: NCT00071110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
Study: NCT04522440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: to relieve the pain of inpatients in the hospice Ward
Description: This study will use pain scale, distress thermometer and POMS to understand whether the patient's pain status have changed.
Study: NCT02695446

Intervention type: DRUG
Group type: OTHER
Intervention: Minocycline
Description: Oral extended release minocycline
Study: NCT03919656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Study: NCT01268462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox+PEP
Description: For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen+PEP
Description: For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox
Description: For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
Study: NCT03337373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Description: A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
Study: NCT00915798

Intervention type: BEHAVIORAL
Intervention: Abstinence
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
Study: NCT01940731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium
Description: 3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
Study: NCT01016925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunnelized perineural catheter
Description: the catheter will be tunneled 2-3 cm subcutaneously.
Study: NCT02220621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked hyaluronic acid gel
Description: After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foleys balloon catheter
Description: After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foleys balloon catheter
Description: After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
Study: NCT03751852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Coaching
Description: 28 classes in 16 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: 28 classes in 16 weeks
Study: NCT01112969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based supportive coaching OSCAR
Description: The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list control group (TAU)
Description: Waiting-list control group (treatment as usual, TAU, no specific intervention)
Study: NCT02372786

Intervention type: DRUG
Group type: OTHER
Intervention: 2,5% lidocaine / 2,5% prilocaine cream
Description: The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
Study: NCT03338491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induction of Implemental Mindset
Description: This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induction of Deliberative Mindset
Description: This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required.
Study: NCT02372786

Intervention type: DRUG
Group type: OTHER
Intervention: 2,5% lidocaine / 2,5% prilocaine cream
Description: The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: 7% lidocaine / 7% tetracaine cream
Description: The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: 7% lidocaine / 7% tetracaine cream
Description: The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser
Description: Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Q-switched nd Yag laser
Description: Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
Study: NCT02384200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitrofurantoin monohydrate/macrocrystalline capsules
Description: 1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampicillin
Description: IV (2 g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin
Description: IV (2 g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin
Description: IV (5 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: IV (5 mg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: IV (1 g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: IV (1 g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: IV (2 g)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: IV (2 g)
Study: NCT01728935

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil 300mg daily
Study: NCT00852267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Carbohydrate, High Saturated Fat Diet
Description: 50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate, High Saturated Fat Diet
Description: 31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate, Low Saturated Fat Diet
Description: 31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
Study: NCT00998621

Intervention type: OTHER
Intervention: Adherence questionnaire
Description: Adherence questionnaire

Intervention type: OTHER
Intervention: Adherence questionnaire
Description: Adherence questionnaire
Study: NCT03622242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain threshold index
Description: In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
Study: NCT01268462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.